Katherine Stueland - Sep 16, 2024 Form 4 Insider Report for GeneDx Holdings Corp. (WGS)

Role
Chief Executive Officer, Director
Signature
/s/ Bridget Brown, Attorney-in-Fact
Stock symbol
WGS
Transactions as of
Sep 16, 2024
Transactions value $
-$394,733
Form type
4
Date filed
9/18/2024, 04:28 PM
Previous filing
Sep 11, 2024
Next filing
Oct 31, 2024

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction WGS Class A Common Stock Options Exercise $0 +18.8K +19.64% $0.00 114K Sep 16, 2024 Direct F1
transaction WGS Class A Common Stock Sale -$395K -10.5K -9.19% $37.59 104K Sep 16, 2024 Direct F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction WGS Restricted Stock Unit Options Exercise $0 -18.8K -9.09% $0.00 188K Sep 16, 2024 Class A Common Stock 18.8K Direct F1, F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Each restricted stock unit ("RSU") represents a contingent right to receive 1 share of the Issuer's Class A Common Stock upon settlement for no consideration.
F2 The sales reported on this Form 4 represent shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of RSUs. The sales were to satisfy tax withholding obligations to be funded by a "sell to cover" transaction.
F3 6.25% vest in quarterly installments over the 4-year period commencing on March 16, 2023 until fully vested, subject to the Reporting Person's continued service to the Issuer on each vesting date.